Asterias Biotherapeutics (NYSEAMERICAN:AST) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) from a buy rating to a hold rating in a research report report published on Wednesday, November 22nd.

According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “

Several other equities research analysts also recently weighed in on AST. ValuEngine downgraded shares of Asterias Biotherapeutics from a hold rating to a sell rating in a research note on Wednesday, August 2nd. HC Wainwright set a $12.00 price target on shares of Asterias Biotherapeutics and gave the stock a buy rating in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Asterias Biotherapeutics has an average rating of Hold and a consensus target price of $9.19.

Shares of Asterias Biotherapeutics (NYSEAMERICAN AST) opened at $2.30 on Wednesday. Asterias Biotherapeutics has a 52 week low of $2.00 and a 52 week high of $5.00.

COPYRIGHT VIOLATION WARNING: “Asterias Biotherapeutics (NYSEAMERICAN:AST) Rating Lowered to Hold at Zacks Investment Research” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://ledgergazette.com/2017/12/05/asterias-biotherapeutics-inc-ast-stock-rating-lowered-by-zacks-investment-research.html.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Get a free copy of the Zacks research report on Asterias Biotherapeutics (AST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply